Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Figures & data

Figure 1 Patient disposition.

Notes: *Patients may appear in more than one exclusion category. **Reasons other than those described in the protocol (eg, newly-diagnosed hypertension, an inability to tolerate other antihypertensive medication, or a lack of response to current antihypertensive medication).
Abbreviations: SBP, systolic blood pressure; V1, baseline; ITT, intention to treat; PP, per protocol.

Table 1 Demographic characteristics (ITT population; n=1,114) and Framingham-eligible subset (n=933)

Demographic characteristics	ITT population (n, %)	Framingham-eligible subset (n, %)
Sex (n, %)	n=1,110	n=919
Men	574 (52.2%)	480 (52.2%)
Women	526 (47.8%)	439 (47.8%)
Age (years)	n=1,114	n=933
Mean ± SD	59.2±12.5	57.7± 12.2
<50	244 (21.9%)	227 (24.3%)
50–59	333 (29.9%)	307 (32.9%)
60–69	295 (26.5%)	238 (25.5%)
≥70	242 (21.7%)	161 (17.3%)
Height (cm)	n=982	n=826
Mean ± SD	164.6± 12.4	164.5±12.5
Weight (kg)	n=1,078	n=902
Mean ± SD	81.6±18.3	81.6±18.3
BMI (kg/m^2)	n=953	n=801
Mean ± SD	30.1±6.6	30.1±6.5
Waist circumference (cm)	n=950	n=794
Mean ± SD	98.3±14.9	98.1±15.2
Race	n=1,097	n=919
White	650 (59.3%)	532 (57.9%)
Black of African heritage or African American	286 (26.1%)	243 (26.4%)
Asian	104 (9.5%)	95 (10.3%)
American Indian or Alaska American	43 (3.9%)	39 (4.2%)
Native Hawaiian or Other Pacific Islander	6 (0.7%)	3 (0.3%)
Other	8 (0.1%)	7 (0.8%)
Smoker status	n=1,114	n=933
Yes	185 (16.6%)	153 (16.4%)
No	929 (83.4%)	780 (83.6%)
Total: HDL-C ratio	(n=660)	(n=563)
	3.5±0.9	3.5±0.9

Note: Sample sizes vary due to lack of recorded data.

Abbreviations: ITT, intention-to-treat; SD, standard deviation; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol.

Table 2 Baseline mean blood pressures and hypertension classification (ITT population; n=1,114) and Framingham-eligible subset (n=933)

	ITT population (n=1,114)	Framingham-eligible subset (n=933)
SBP (mmHg) (n=1,114)	155.8±12.1	155.9±12.0
DBP (mmHg) (n=1,112)	90.36±9.9	91.3±9.4
PBP (mmHg) (n=1,112)	65.46±14.2	64.6±13.8
Type of hypertension	n=1,098	n=931
Isolated systolic hypertension	386 (35.2%)	292 (31.4%)
Isolated diastolic hypertension	32 (2.9%)	28 (3%)
Diastolic-systolic hypertension	643 (58.6%)	584 (62.7%)
No hypertension*	37 (3.4%)	27 (2.9%)

Notes: Blood pressure data are mean ± standard deviation.

* SBP <140 mmHg and DBP <90 mmHg.

Abbreviations: DBP, diastolic blood pressure; ITT, intention-to-treat; PBP, pulse blood pressure; SBP, systolic blood pressure.

Figure 2 Baseline Framingham CHD risk status, according to methodology.

Abbreviation: CHD, coronary heart disease.

Figure 3 Shifts in Framingham CHD risk distribution during treatment.

Notes: (A) n=892 and 811 for baseline and end of study, respectively. (B) n=540 and 424 for baseline and end of study, respectively. (C) n=546 and 427 for baseline and end of study, respectively.
Abbreviation: CHD, coronary heart disease.

Figure 4 Aggregate shift in Framingham CHD risk distribution during treatment.

Abbreviation: CHD, coronary heart disease.

Table 3 Absolute mean change (± SD) of calculated Framingham CHD risk using formula, stratified by age and sex

Men (n=202)	−2.9±3.9
Women (n=172)	−1.1±1.0
	P<0.001
<50 years (n=207)	−1.1±1.3
50–59 years (n=297)	−2.1±2.3
60–69 years (n=228)	−1.9±2.7
≥70 years (n=155)	−3.2±4.9
	P<0.001

Note: Data are percentages.

Abbreviations: CHD, coronary heart disease; SD, standard deviation.

Table 4 Distribution on change in risk factors (SBP, total and HDL cholesterol, and smoker status) during the survey among patients whose overall CHD risk decreased by at least one class

	Subjects whose recorded Framingham CHD risk decreased at least one class (n=233) n (%)	Subjects whose calculated* Framingham CHD risk decreased at least one class (n=154) n (%)	Subjects whose calculated# Framingham CHD risk decreased at least one class (n=170) n (%)
Decrease of SBP of at least one class	204 (87.6%)	138 (89.6%)	149 (87.6%)
Decrease of total cholesterol of at least one class	84 (36.1%)	37 (24.0%)	36 (21.2%)
Increase of HDL-cholesterol of at least one class	22 (9.4%)	0 (0%)	0 (0%)
Smoking cessation	12 (5.2%)	8 (5.2%)	7 (4.1%)

Notes:

* Using tables of the Framingham point scores.

# Using formulae.

Abbreviations: CHD, coronary heart disease; HDL, high-density lipoprotein; SBP, systolic blood pressure.

Table 5 Summary of suspected adverse drug reactions in the Canadian POWER safety population (N=1315)

	Number of SADRs (Percentage of total SADRs [n=119])	Number of patients with ≥1 SADR (Percentage of total patients [n=1315])
SADRs leading to study discontinuation	83 (69.7%)	51 (3.9%)
Serious SADRs	3 (2.5%)	3 (0.2%)
Severe SADRs	9 (7.6%)	7 (0.5%)
Deaths	2 (1.7%)	2 (0.2%)

Abbreviations: SADRs, suspected adverse drug reactions; POWER, Physicians’ Observational Work on Patient Education According to their Vascular Risk.